|Day Low/High||114.74 / 119.81|
|52 Wk Low/High||61.61 / 115.14|
A rotation that started as the minor chord of the rotational symphony and is now the major one.
Barring a close below $46, we are likely to see ABT remain firm and work higher.
Female representation among the top 10% of earners at the NAFE top companies increased 2% to 41%, the highest since 2013.
It's a wonder to me how split this market really is.
Medtronic, Abbott Labs and Becton Dickinson appear to be offering buying opportunities.
Earnings take center stage again with a disappointment from IBM and a better-than-expected performance from Morgan Stanley dividing markets.
Their overseas business has been carrying them.
We know that we are in the era when index managers are ascendant.
There are nearly too many surging sectors to count.
ABT could be on course for 10% earnings growth this year, but will investors reward the company with a higher share price?
Start 2017 on the right foot by selling your holdings in these five stocks.
The Federal Trade Commission says Abbott Laboratories can proceed with its proposed $25 billion acquisition of St. Jude Medical.
Here is a look at some stocks that are poised for excellent dividend returns in 2017.
Look for ABT's declining trend to continue a while longer.
"You see, in this world there's two kinds of people, my friend: Those with loaded guns and those who dig. You dig." -- Blondie in "The Good, the Bad and the Ugly." I did very little today. Markets were higher from the get-go and seemed "stuck" nea...
Shares of the medical-device giant were climbing after unveiling strong earnings.
Political pressure is weighing on drug and medical device stocks including Abbott Labs and St. Jude, says Jim Cramer.
St. Jude's warning about battery risks in its implanted heart devices are big but will likely not disrupt its deal with Abbott Labs.
U.S. stocks ended Friday's session lower as a crude oil selloff pressures the energy sector and nerves over next week's Federal Reserve meeting peak.